BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

...S100 calcium binding protein A4 S100A7 (psoriasin) - S100 calcium binding protein A7 S100A8 (calgranulin A; MRP8) - S100 calcium binding protein...
...A7 S100A8 (calgranulin A; MRP8) - S100 calcium binding protein A8 S100A9 (calgranulin B; MRP14) - S100 calcium binding protein...
...glycation endproducts (RAGE) S100 calcium binding protein A4 (S100A4) Tumor necrosis factor (TNF) S100 calcium binding protein A8 (S100A8) (calgranulin A) (MRP8) S100 calcium binding protein...
BioCentury | Sep 19, 2019
Distillery Therapeutics

S100A10 and SP1 identified as ALS targets

...Inc. discontinued marketing of Mithracin for cancer in 2000. TARGET/MARKER/PATHWAY: Sp1 transcription factor (SP1); S100 calcium binding protein...
...Aug. 22, 2019 doi:10.1038/s41467-019-11637-4 CONTACT: Bernardo Moreno-López, University of Cadiz, Cadiz, Spain email: bernardo.moreno@uca.es Claire Quang S100 calcium binding protein...
BioCentury | Sep 10, 2019
Distillery Therapeutics

S100A9 could normalize metabolic imbalances from insulin deficiency

...maximum lifespan from 16.5 and 34 days to 34.5 and 80 days, respectively. TARGET/MARKER/PATHWAY: S100 calcium binding protein...
...Switzerland email: giorgio.ramadori@unige.ch CONTACT: Roberto Coppari, same affiliation as above email: roberto.coppari@unige.ch Claire Quang University of Geneva S100 calcium binding protein...
BioCentury | Feb 15, 2019
Tools & Techniques

Heartening predictors in diabetes

New biomarkers of cardiovascular risk could relieve a decade-old bottleneck for diabetes drug development, but validating them will require companies to invest in strategic trial designs, and public and private stakeholders to pool thinking. As...
BioCentury | Aug 10, 2018
Clinical News

Active, Teva's laquinimod misses in Phase II for HD

...Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA), Petah Tikva, Israel Product: Laquinimod Business: Neurology Molecular target: S100 calcium binding protein...
...NA Chris Lieu Nerventra (Brand), 5062 (Compound #), laquinimod (Generic), SAIK-MS (Informal) Active Biotech AB Teva Pharmaceutical Industries Ltd. S100 calcium binding protein...
BioCentury | Mar 2, 2018
Clinical News

Glenmark reports Phase IIa data for anti-OX40 mAb in atopic dermatitis

...severe atopic dermatitis showing that GBR 830 reduced mRNA biomarkers of disease activity, including S100 calcium binding protein...
BioCentury | Dec 8, 2017
Clinical News

Active, Teva's laquinimod misses in Phase II for PPMS

...Ltd. (NYSE:TEVA; Tel Aviv:TEVA), Petah Tikva, Israel Product: Laquinimod (SAIK-MS) Business: Autoimmune Molecular target: S100 calcium binding protein...
...MRI data Status: Phase II data Milestone: NA Jaime De Leon laquinimod Nerventra SAIK-MS Active Biotech AB Teva Pharmaceutical Industries Ltd. S100 calcium binding protein...
BioCentury | Oct 5, 2017
Translation in Brief

SSRIs' first responders

...and 2010, a Rockefeller team led by Paul Greengard showed in normal mice that S100 calcium binding protein...
...5-HT1B Receptor Function by p11 in Depression-Like States." Science (2006) Winnie Pong, Staff Writer The Rockefeller University S100 calcium binding protein...
BioCentury | Sep 14, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2017

...ovarian cancer. University of South Australia and SA Pathology Distillery Therapeutics Cardiovascular Arrhythmia Histidine rich calcium binding protein...
BioCentury | Aug 29, 2017
Distillery Therapeutics

Cancer

...a humanized antibody against S100A4, in preclinical development to treat solid tumors. TARGET/MARKER/PATHWAY: S100 calcium binding protein...
...doi:10.1158/0008-5472.CAN-17-1294 CONTACT: Kyuson Yun, The Jackson Laboratory, Bar Harbor, Maine email: kyun@houstonmethodist.org Hongjiang Li The Jackson Laboratory S100 calcium binding protein...
Items per page:
1 - 10 of 114